The BINSA Act expands national security screening under the Defense Production Act to restrict U.S. investment and technology transfer in biotechnology that could accelerate China's control over the pharmaceutical innovation supply chain.
John Moolenaar
Representative
MI-2
The Biotech Investment National Security Act (BINSA Act) aims to safeguard U.S. national security by addressing risks posed by China's dominance in biotechnology. It amends the Defense Production Act to include biotechnology—specifically pharmaceutical and biologics development—under outbound investment screening authorities. This action seeks to prevent U.S. capital and intellectual property from accelerating China's control over critical therapeutic supply chains.
BINSA Act Targets $136 Billion in Biotech Deals: New Restrictions on U.S. Pharmaceutical Investment in China Set for 2026.
The BINSA Act is a major move to treat the biotech industry like a national security asset, similar to how the government handles military tech or semiconductors. By expanding the Defense Production Act, the bill aims to stop U.S. money and intellectual property from fueling China’s pharmaceutical growth. It specifically targets licensing deals, joint ventures, and equity purchases, citing a massive $136 billion in cross-border deals in 2025 as a reason for concern. The goal is to prevent the U.S. from becoming strategically dependent on China for future medicines and biologics.
The New Red Tape for Biotech
Under Section 3, the bill adds biotechnology to the list of sectors under federal outbound investment screening. This isn't just about large corporations; it covers drug discovery platforms, clinical research, and manufacturing know-how. For a researcher at a startup or a mid-sized pharmaceutical company, this means that a plan to license a new therapeutic compound to a partner in China could soon be flagged as a 'restricted activity.' The bill specifically mentions 'licensing a prohibited technology' (Section 3) as a new hurdle, which could turn a standard business deal into a national security review.
Defining the Boundaries
The Secretary of the Treasury has one year to write the specific rules on what 'biotechnology' actually includes (Section 4). While the bill explicitly excludes things like agricultural tech or basic college research, it casts a wide net over anything related to human health. If you are an investor or an employee in a firm that relies on global clinical trials or international manufacturing partnerships, the next year will be a waiting game. The Treasury will decide which specific technologies are 'prohibited' or 'notifiable,' potentially changing the financial viability of projects that rely on Chinese capital or infrastructure.
Assessing the Fallout
Within 60 days of the bill passing, the Secretary of Defense must report on how U.S. capital flows into China affect military readiness (Section 5). This highlights the bill's skeptical view of international collaboration in science. While the move is designed to protect American innovation, it could create a 'chilling effect' for U.S. companies. For example, a biotech firm might find it harder to fund expensive clinical trials if they can't tap into Chinese markets or partners, potentially slowing down the development of new drugs here at home while the government figures out where to draw the line.